Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 3, 1996, Pages 627-632

  Madaras Kelly, Karl J ^a,c,d   Ostergaard, Beth E ^a,b   Hovde, Laurie Baeker ^b   Rotschafer, John C ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b REGIONS HOSPITAL   (United States)

^c IDAHO STATE UNIVERSITY   (United States)

^d Boise VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REGRESSION ANALYSIS; STRAIN DIFFERENCE;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; KINETICS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; OFLOXACIN; PSEUDOMONAS AERUGINOSA; REGRESSION ANALYSIS;

EID: 0030030549     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.3.627     Document Type: Article

References (21)

1. Bauernfeind, A., C. Petermuller, and B. Heinrich. 1986 Dependence of bacterial activity and mutant selection of 4-quinolones on their serum concentration levels Infection 14(Suppl. 1):S26-S30.
2. Blaser, J., B. B. Stone, and M. C. Groner. 1987 Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother 31:1054-1060.
3. Drusano, G. L., D. E. Johnson, M. Rosen, and H. C. Standiford. 1993. Pharmacodynamics of a fluoroqninolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 37:483-490.
4. Forrest, A., M. Amantea, D. A. Collins, S. Chodosh, and J. J. Schentag. 1993. Pharmacodynamics (PDs) of oral OPC-17116 in patients (pts) with acute bacterial exacerbations of chronic bronchitis, abstr 81, p. 134. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
5. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
6. Haag, R., P. Lexa, and I. Werkhauser. 1986 Artifacts in dilution pharmacokinetic models caused by adherent bacteria. Antimicrob. Agents Chemother 29:765-768.
7. Herman, V. K., F. N. Konstantinides, R. A. Zabinski, A. Krinke, K. J. Walker, and J. Rotschafer. 1991. Abstr. 336 In Program and abstracts of the 17th Meeting of the Federation of American Societies for Experimental Microbiology. Federation of American Societies for Experimental Microbiology.
8. Hyatt, J. M., D. E. Nix, and J. J. Schentag. 1994. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. Antimicrob. Agents Chemother. 38:2730-2737.
9. Leggett, J. E., S. Ebert, B. Fantin, and W. A. Craig. 1991. Comparative dose effect relations at several dosing intervals for beta-lactam, aminoglycoside, and quinolone antibiotics against gram negative bacilli in a murine thigh-infection and pneumonitis models. Scand. J Infect. Dis. 74(Supp.l):179-184.
10. Lerner, S. A., C. A. Laviert, and E. M. Quimosng. 1988. Selection of ciprofloxacin mutants in-vitro from clinical isolates of Pseudomonas aeruginosa and other bacteria in an in-vitro two compartment capillary model. Rev. Infect. Dis. 10(Suppl. 1):34-35
11. 10a Madaras-Kelly, K. J., B. E. Ostergaard, L. Baeker Hovde, and J. C. Rotschafer. 1994. Identification of an area under the inhibitory curve (AUIC) threshold breakpoint for two fluoroquinolones utilizing an in vitro pharmacodynamic model, abstr. A85, p 146. In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology. Washington, D.C.
12. McFarland, M. M., E. M. Scott, and A. L. W. Po. 1994. Time-survival studies for quantifying effects of azlocillin and tobramycin on Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 38:1271-1276.
13. Nightingale, C. H. 1993 Pharmacokinetic considerations in quinolone therapy. Pharmacotherapy 13(2 pt 2):34S-38S.
14. Peloquin, C. A., T. J. Cumbo, and D. E. Nix. 1989. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections: impact of plasma concentrations, organism, minimum inhibitory concentration and clinical condition of bacterial eradication. Arch. Intern Med 149: 2269-2273.
15. Sawchuk, R. J., D. E. Zaske, R. J. Cipolle, W. A. Wargin, and R. G. Strate. 1977. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin. Pharmacol. Ther. 21:362-369.
16. Schentag, J. J., D. E. Nix, and M. H. Adelman. 1991. Mathematical examination of dual individualization principles. Relationships between AUC above MIC and area under the inhibitory curve (AUC/MIC) for cefmenoxime, ciprofloxacin. and tobramycin. DICP-Ann Pharmacother. 25:1050-1057.
17. Schentag, J. J., D. E. Nix, and A. Forrest. 1993. Pharmacodynamics of the fluoroquinolones, p. 259-271. In D C. Hooper and J S. Wolfson (ed.), Quinolone antimicrobial agents, 2nd ed American Society for Microbiology, Washington, D.C.
18. Yeh, K. C., and K. C. Kwan. 1978. A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximations. J Pharmacokinet. Biopharm. 6:79.
19. Zabinski, R. A., A. J. Krinke, K. J. Walker, S. S. Gilliland, and J. C. Rotschafer. 1993. Elimination of quinolone carryover through the use of antibiotic removal binding resins. Antimicrob Agents Chemother. 37:1377-1379.
20. Zabinski, R. A., K. Vance-Bryan, K. J. Walker, A. Krinke, J. A. Moody, and J. C. Rotschafer. 1993. Evaluation of the activity of temafioxacin versus Bacteroides fragilis using an in vitro pharmacodynamic system. Antimicrob Agents Chemother. 37:2454-2458.
21. Zar, J. H. 1984. Multiple comparisons, p. 185-206. In Biostatistical analysis. 2nd ed Prentice-Hall, Inc., Englewood Cliffs, NJ